ADRA1A: GPCR Worsening Fear, Anxiety, Sleep and Movement (G148)

Target Name: ADRA1A

NCBI ID: G148

ADRA1A

ADRA1A: GPCR Worsening Fear, Anxiety, Sleep and Movement

The 伪-1A adrenoreceptor (ADRA1A) is a G protein-coupled receptor located in the brain and plays a crucial role in regulating various physiological processes in the body. It is one of the most abundant adrenoreceptors in the central nervous system and is involved in the regulation of motivation, emotion, and behavior.

ADRA1A is a member of the G protein-coupled receptor family, which is a large superfamily of transmembrane proteins that play a key role in cellular signaling. The 伪-1A subfamily of GPCRs is composed of a diverse range of structurally similar but functionally distinct subtypes. These subtypes are characterized by different extracellular interactions, such as the presence or absence of an intracellular loop, a cytoplasmic tail, or a modulation of activity by different signaling molecules.

ADRA1A is a GPCR that is expressed in many different tissues and cells throughout the body, including the brain, heart, and peripherals. It is primarily localized to the basal ganglia, which is a subcortical structure that plays a key role in the coordination of movement, emotion, and behavior.

ADRA1A is involved in the regulation of a wide range of physiological processes that are critical for brain function. One of its most well-studied functions is its role in the regulation of motivation and reward. Studies have shown that activation of ADRA1A can increase the release of dopamine in the brain, which is a neurotransmitter that is involved in the regulation of motivation and reward. This increase in dopamine release can lead to feelings of pleasure and motivation.

In addition to its role in motivation and reward, ADRA1A is also involved in the regulation of fear and anxiety. Studies have shown that activation of ADRA1A can increase the release of cortisol, a hormone that is involved in the regulation of stress and anxiety. This increase in cortisol release can lead to feelings of fear and anxiety.

ADRA1A is also involved in the regulation of sleep and wakefulness. Studies have shown that the activation of ADRA1A can disrupt the normal patterns of sleep and wakefulness and can cause insomnia-like symptoms. This disruption in sleep and wakefulness can have negative consequences on overall health and well-being.

In addition to its role in motivation, fear, and anxiety, ADRA1A is also involved in the regulation of other physiological processes that are critical for brain function. It is involved in the regulation of movement, including the coordination of movements and the control of body position. It is also involved in the regulation of appetite and metabolism, as well as the regulation of body temperature.

In conclusion, ADRA1A is a GPCR that plays a crucial role in the regulation of various physiological processes in the body. Its most well-studied functions include the regulation of motivation, reward, fear, anxiety, and sleep. Given its involvement in these processes, ADRA1A is an attractive drug target and may have potential as a treatment for a variety of neurological and psychiatric disorders.

Protein Name: Adrenoceptor Alpha 1A

Functions: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes

The "ADRA1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADRA1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets